|
|
Vaccine Detail
|
Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine |
| Vaccine Information |
- Vaccine Name: Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007236
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Gla
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Allogeneic tumor cells are genetically modified to express α-(1, 3) galactosyltransferase (Berzofsky et al., 2004). Colon carcinoma cells are used to express the αGal antigen on their cellular surface (Unfer et al., 2003).
- Description: An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes. (NCIT_C113647).
|
| Host Response |
|
|
| References |
Berzofsky et al., 2004: Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. The Journal of clinical investigation. 2004; 113(11); 1515-1525. [PubMed: 15173875].
NCIT_C113647: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113647]
Unfer et al., 2003: Unfer RC, Hellrung D, Link CJ Jr. Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer research. 2003; 63(5); 987-993. [PubMed: 12615713].
|
|
